Lercaril

Enalapril maleate and lercanidipine hydrochloride, the active ingredients in Lercaril, are an ACE inhibitor and a dihydropyridine calcium‑channel blocker presented as a tablet for oral use. They lower elevated blood pressure in adult patients with hypertension and provide a combined therapeutic approach that improves vascular tone and reduces cardiovascular risk.

GNH USA supplies Lercaril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics for cross‑border medication distribution.

Lercaril combines an ACE inhibitor and a calcium‑channel blocker to treat hypertension, a condition characterized by persistently high arterial pressure.

Hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. Essential hypertension: provides additive blood‑pressure control when monotherapy is insufficient. High blood pressure: improves overall cardiovascular risk profile by targeting two complementary pathways.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache, often mild and transient. - Flushing or warmth sensation. - Peripheral edema, typically mild swelling of the ankles. - Persistent dry cough, characteristic of ACE inhibition. - Fatigue or general weakness.

Serious or Rare Side Effects: - Angioedema involving face, lips, tongue or airway. - Severe hypotension causing fainting or shock. - Hepatic dysfunction with elevated liver enzymes. - Acute myocardial infarction or worsening heart failure. - Life‑threatening arrhythmias. - Acute renal failure, especially in patients with pre‑existing kidney disease.

Before initiating therapy, clinicians should assess baseline blood pressure, renal function and electrolyte status.

Monitor blood pressure regularly to avoid excessive hypotension. Assess renal function periodically, especially in patients with chronic kidney disease. Check serum potassium and sodium levels when combined with diuretics. Use caution in patients with hepatic impairment or a history of angioedema. Store at below 25°C: keep in the original pack, protect from moisture.

Lercaril may interact with several drug classes that affect blood pressure or electrolyte balance.

Major Interactions (Avoid): - Concomitant use of aliskiren in diabetic patients. - Potassium‑sparing diuretics that increase serum potassium. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may blunt antihypertensive effect.

Moderate Interactions (Monitor Closely):\n- Thiazide diuretics, which can enhance hypotensive response. - Strong CYP3A4 inhibitors or inducers that may alter lercanidipine levels.